NDLI: Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Siegel, Jerry Jorgenson, James Johnson, Philip E. Brophy, Donald F. Comstock, Thomas Feng, Amy Audhya, Paul
Spatial Coverage	United States
Description	Country affiliation: United States Author Affiliation: Siegel J ( College of Pharmacy, The Ohio State University Medical Center, Columbus 43210, USA. jerry.siegel@osumc.edu)
Abstract	PURPOSE: Erythropoiesis-stimulating agent (ESA) use in the outpatient and inpatient settings through pharmacist-conducted, hospital-based chart audits is examined and discussed. METHODS: Data from four hospital chart audits conducted in 250 hospitals between October 2005 and July 2006 were pooled for analyses. Eligible hospitals were categorized by ESA sales volume, with approximately equal numbers randomly selected from each decile. The last five inpatients and outpatients within each specified month receiving either darbepoetin alfa or epoetin alfa were evaluated. Study variables by setting included ESA use, prescriber specialty, and dosage regimen. RESULTS: The most common hospital locations of ESA administration were a cancer center in the outpatient setting (49%) and general medicine (57%) in the inpatient setting. ESA prescribers were most commonly hematologists and oncologists in the outpatient setting, and nephrologists were the most common prescribers in the inpatient setting. In the outpatient analysis, 2155 patients were prescribed darbepoetin alfa and 3106 were prescribed epoetin alfa. The predominant administration frequencies were every two weeks and once weekly for darbepoetin alfa, and once weekly for epoetin alfa. In the inpatient analysis, 1633 patients were prescribed darbepoetin alfa and 3231 were prescribed epoetin alfa. The predominant administration frequencies were once weekly for darbepoetin alfa and once weekly and three times weekly for epoetin alfa. Common uses for both ESAs were chemotherapy-induced anemia (outpatient setting) and anemia of end-stage renal disease with chronic dialysis (inpatient setting). There was considerable variability in ESA dosages and administration frequencies in both settings within all patient groups when analyzed by specified use. CONCLUSION: ESA use differed between outpatient and inpatient settings in indication, frequency of administration, and specialty of the prescriber.
File Format	HTM / HTML
ISSN	10792082
Issue Number	18
Volume Number	65
e-ISSN	15352900
Journal	American Journal of Health-System Pharmacy
Language	English
Publisher	American Society of Health-System Pharmacists
Publisher Date	2008-09-15
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Erythropoietin United States Humans Discipline Pharmacy Recombinant Proteins Drug Utilization Review Journal Article Physician's Practice Patterns Inpatients Etiology Epoetin Alfa Hematinics Renal Insufficiency, Chronic Adverse Effects Darbepoetin Alfa Anemia Complications Hospital Bed Capacity, 100 To 299 Drug Therapy Antineoplastic Agents Administration & Dosage Therapeutic Use Chemically Induced Hospitals Outpatients Statistics & Numerical Data Analogs & Derivatives
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacy Health Policy

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Reimbursement for erythropoiesis-stimulating agents poses challenges.

Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.

Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.

Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial

Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.

Use and cost of erythropoiesis-stimulating agents in patients with cancer.

Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

Similar Documents

Reimbursement for erythropoiesis-stimulating agents poses challenges.

Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.

Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.

Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial

Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.

Use and cost of erythropoiesis-stimulating agents in patients with cancer.

Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.